PHOTO
Cairo, Egypt: - Novo Nordisk, the leading global diabetes healthcare company, launched Ryzodeg®, the latest innovation for management of diabetes, in Egypt. The new drug is the outcome of extensive research conducted by Novo Nordisk over many decades aiming to achieve a major change to diabetics’ lifestyles in Egypt and worldwide. Ryzodeg® was approved by FDA in 2015 and EMA in 2013, and It is now commercially available in 31 countries, including Switzerland, Japan, KSA and UAE.
When treated with once-daily Ryzodeg®, people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily insulin dose and significantly reduced risk of nocturnal hypoglycemia in the step-by-step trial compared with once-daily insulin glargine U100 plus once-daily insulin aspart after 26 weeks. Ryzodeg® is a combination of insulin degludec and insulin aspart (IDegAsp) in one pen for the treatment of people with type 2 diabetes.
The clinical effects of Ryzodeg® were presented at a press conference held by Novo Nordisk in Cairo today. The event was attended by Mrs. Camilla Rasmussen, Charge d’ Affairs, Embassy of Denmark in Egypt; Dr. Ibrahim Al Ibrashy, Professor of Internal Medicine and Diabetes, Cairo University and Member of the National Committee for Diabetes and Endocrinology; Dr. Samir Helmy Assaad-Professor of Internal Medicine and Diabetes, Alexandria University; and Dr. Ayman Hassan, VP and General Manager of Novo Nordisk Egypt.
Commenting on this scientific breakthrough, Dr. Samir Helmy Assaad, Professor of Internal Medicine and Diabetes, Alexandria University said that “Ryzodeg® has unique clinical features, as it is a combination of ultra-long acting basal Insulin degludec (Tresiba®) and fast acting insulin aspart (Novo Rapid®) in one pen for the treatment of people with type 2 diabetes. The burden of diabetes is not limited to acute symptoms associated with hyperglycemia, as the complications are more life-threatening and include Cardiovascular diseases, diabetic kidney disease, diabetic foot, retinopathy and others. Patients can suffer from these chronic complications for the rest of their lives if blood sugar levels are not properly managed. dherence to insulin use is one of the key factors of proper diabetes management. Simplicity is one of the most important factors that doctors need to take into consideration when they are prescribing insulin to allow adherence and proper control. Ryzodeg® is one of the simplest insulin options for treatment of type 2 diabetes
“Diabetes is one of the most pressing health issues and most prevalent chronic diseases in Egypt and worldwide. More than 8.9 million Egyptians are suffering from diabetes, representing 15.2% of the total adult population. Egypt ranks ninth highest country in the world in terms of diabetes prevalence rates,” said Dr. Ibrahim Al Ibrashy, Professor of Internal Medicine and Diabetes, Cairo University and Member of the National Committee for Diabetes and Endocrinology. “Among diabetics, hypoglycemia represents one of the major challenges for doctor and patient alike. The mild and moderate symptoms may include tachycardia, trembling, hunger sensation, sweating, and lack of concentration, while severe symptoms require immediate medical care and may lead to hypoglycemic coma. Nocturnal hypoglycemic episode is a dangerous type of hypoglycemia and a real concern for people with diabetes, because it is a sudden and unpredictable episode and its symptoms are not easily identified when they occur. The clinical studies show the efficacy of Ryzodeg® in lowering rates of nocturnal symptomatic hypoglycemic episodes by 45% compared to conventional insulin regimens. Eventually, Ryzodeg® is one of the safest insulin types for people with type 2 diabetes.”
Dr. Ayman Hassan, General Manager of Novo Nordisk Egypt, underlined the company’s efforts to introduce the highest level of healthcare to Egyptian diabetics, in order to alleviate burdens and health complications imposed by this chronic disease, while changing lives of people with diabetes. Dr. Hassan added that the launch of Ryzodeg® with its unique health benefits aligns with the company’s endeavors to introduce the most advanced treatment and healthcare solutions to address many health challenges, on top of which are diabetes and obesity, and as a global company Novo Nordisk allocates 2 billion Euros every year for R&D. Dr. Hassan reaffirms the company’s commitment to build capacity and skills of Egyptian doctors and healthcare providers, in addition to establishing of specialized diabetes healthcare centers in cooperation with the Ministry of Health and the National Health Insurance Authority.
At the end of the press conference, Mrs. Camilla Rasmussen, Charge d’ Affairs, Embassy of Denmark in Egypt, discussed the advancement of mutual Egyptian-Danish Relations on both political and economic levels, noting that Novo Nordisk is the largest and most important Danish company operating in Egypt and worldwide. Danish investments in Egypt reach EGP 5 billion across several economic sectors, including health, transport, freight, and food products. Mrs. Rasmussen noted the importance of the event where a Danish company is introducing its latest scientific breakthrough for a better life to all Egyptians with diabetes.
-Ends-
About Novo Nordisk
Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 40,000 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
For further information, please contact:
Mai Mohsen: 01025284447
Mohamed Kandil: 01066861630
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
